Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Angel One Q4 Results: Profit soars 84% YoY in a quarter of stock market crash
Angel One reported strong March quarter results with profit rising 84% YoY, driven by higher trading volumes, improved monetisation, and operating leverage. Client activity rebounded,